175 related articles for article (PubMed ID: 35086832)
1. Forskolin-induced organoid swelling is associated with long-term cystic fibrosis disease progression.
Muilwijk D; de Poel E; van Mourik P; Suen SWF; Vonk AM; Brunsveld JE; Kruisselbrink E; Oppelaar H; Hagemeijer MC; Berkers G; de Winter-de Groot KM; Heida-Michel S; Jans SR; van Panhuis H; van der Eerden MM; van der Meer R; Roukema J; Dompeling E; Weersink EJM; Koppelman GH; Vries R; Zomer-van Ommen DD; Eijkemans MJC; van der Ent CK; Beekman JM
Eur Respir J; 2022 Aug; 60(2):. PubMed ID: 35086832
[TBL] [Abstract][Full Text] [Related]
2. Stratifying infants with cystic fibrosis for disease severity using intestinal organoid swelling as a biomarker of CFTR function.
de Winter-de Groot KM; Janssens HM; van Uum RT; Dekkers JF; Berkers G; Vonk A; Kruisselbrink E; Oppelaar H; Vries R; Clevers H; Houwen RHJ; Escher JC; Elias SG; de Jonge HR; de Rijke YB; Tiddens HAWM; van der Ent CK; Beekman JM
Eur Respir J; 2018 Sep; 52(3):. PubMed ID: 30166324
[TBL] [Abstract][Full Text] [Related]
3. Forskolin-induced swelling of intestinal organoids correlates with disease severity in adults with cystic fibrosis and homozygous F508del mutations.
de Winter-de Groot KM; Berkers G; Marck-van der Wilt REP; van der Meer R; Vonk A; Dekkers JF; Geerdink M; Michel S; Kruisselbrink E; Vries R; Clevers H; Vleggaar FP; Elias SG; Heijerman HGM; van der Ent CK; Beekman JM
J Cyst Fibros; 2020 Jul; 19(4):614-619. PubMed ID: 31735562
[TBL] [Abstract][Full Text] [Related]
4. FDA-approved drug screening in patient-derived organoids demonstrates potential of drug repurposing for rare cystic fibrosis genotypes.
de Poel E; Spelier S; Hagemeijer MC; van Mourik P; Suen SWF; Vonk AM; Brunsveld JE; Ithakisiou GN; Kruisselbrink E; Oppelaar H; Berkers G; de Winter de Groot KM; Heida-Michel S; Jans SR; van Panhuis H; Bakker M; van der Meer R; Roukema J; Dompeling E; Weersink EJM; Koppelman GH; Blaazer AR; Muijlwijk-Koezen JE; van der Ent CK; Beekman JM
J Cyst Fibros; 2023 May; 22(3):548-559. PubMed ID: 37147251
[TBL] [Abstract][Full Text] [Related]
5. Pancreatitis among patients with cystic fibrosis: correlation with pancreatic status and genotype.
De Boeck K; Weren M; Proesmans M; Kerem E
Pediatrics; 2005 Apr; 115(4):e463-9. PubMed ID: 15772171
[TBL] [Abstract][Full Text] [Related]
6. Forskolin induced swelling (FIS) assay in intestinal organoids to guide eligibility for compassionate use treatment in a CF patient with a rare genotype.
Aalbers BL; Brunsveld JE; van der Ent CK; van den Eijnden JC; Beekman JM; Heijerman HGM
J Cyst Fibros; 2022 Mar; 21(2):254-257. PubMed ID: 35110005
[TBL] [Abstract][Full Text] [Related]
7. Correction of CFTR function in intestinal organoids to guide treatment of cystic fibrosis.
Ramalho AS; Fürstová E; Vonk AM; Ferrante M; Verfaillie C; Dupont L; Boon M; Proesmans M; Beekman JM; Sarouk I; Vazquez Cordero C; Vermeulen F; De Boeck K;
Eur Respir J; 2021 Jan; 57(1):. PubMed ID: 32747394
[TBL] [Abstract][Full Text] [Related]
8. Correctors (specific therapies for class II CFTR mutations) for cystic fibrosis.
Southern KW; Patel S; Sinha IP; Nevitt SJ
Cochrane Database Syst Rev; 2018 Aug; 8(8):CD010966. PubMed ID: 30070364
[TBL] [Abstract][Full Text] [Related]
9. rAAV-CFTRΔR Rescues the Cystic Fibrosis Phenotype in Human Intestinal Organoids and Cystic Fibrosis Mice.
Vidović D; Carlon MS; da Cunha MF; Dekkers JF; Hollenhorst MI; Bijvelds MJ; Ramalho AS; Van den Haute C; Ferrante M; Baekelandt V; Janssens HM; De Boeck K; Sermet-Gaudelus I; de Jonge HR; Gijsbers R; Beekman JM; Edelman A; Debyser Z
Am J Respir Crit Care Med; 2016 Feb; 193(3):288-98. PubMed ID: 26509335
[TBL] [Abstract][Full Text] [Related]
10. Prediction of Real-World Long-Term Outcomes of People with CF Homozygous for the F508del Mutation Treated with CFTR Modulators.
Muilwijk D; Bierlaagh M; van Mourik P; Kraaijkamp J; van der Meer R; van den Bor R; Heijerman H; Eijkemans R; Beekman J; van der Ent K
J Pers Med; 2021 Dec; 11(12):. PubMed ID: 34945848
[TBL] [Abstract][Full Text] [Related]
11. [Relation between gene mutations and pancreatic exocrine function in patients with cystic fibrosis].
Radivojević D; Guć-Sćekić M; Djurisić M; Lalić T; Minić P; Kanavakis E
Srp Arh Celok Lek; 2001; 129 Suppl 1():6-9. PubMed ID: 15637983
[TBL] [Abstract][Full Text] [Related]
12. Forskolin-induced Swelling in Intestinal Organoids: An In Vitro Assay for Assessing Drug Response in Cystic Fibrosis Patients.
Boj SF; Vonk AM; Statia M; Su J; Vries RR; Beekman JM; Clevers H
J Vis Exp; 2017 Feb; (120):. PubMed ID: 28287550
[TBL] [Abstract][Full Text] [Related]
13. Novel CFTR mutations in a Korean infant with cystic fibrosis and pancreatic insufficiency.
Choe YJ; Ko JS; Seo JK; Han JJ; Shim JO; Koh YY; Lee R; Ki CS; Kim JW; Kim JH
J Korean Med Sci; 2010 Jan; 25(1):163-5. PubMed ID: 20052365
[TBL] [Abstract][Full Text] [Related]
14. Targeted locus amplification reveals heterogeneity between and within CFTR genotypes and association with CFTR function in patient-derived intestinal organoids.
Lefferts JW; Boersma V; Nieuwenhuijze NDA; Suen SWF; Hajo K; Collantes NS; Vermeulen C; Groeneweg T; Hagemeijer MC; de Jonge HR; van der Ent CK; Splinter E; Beekman JM
J Cyst Fibros; 2023 May; 22(3):538-547. PubMed ID: 37100706
[TBL] [Abstract][Full Text] [Related]
15. Human Nasal Epithelial Organoids for Therapeutic Development in Cystic Fibrosis.
Liu Z; Anderson JD; Deng L; Mackay S; Bailey J; Kersh L; Rowe SM; Guimbellot JS
Genes (Basel); 2020 May; 11(6):. PubMed ID: 32485957
[TBL] [Abstract][Full Text] [Related]
16. Targeting G542X CFTR nonsense alleles with ELX-02 restores CFTR function in human-derived intestinal organoids.
Crawford DK; Mullenders J; Pott J; Boj SF; Landskroner-Eiger S; Goddeeris MM
J Cyst Fibros; 2021 May; 20(3):436-442. PubMed ID: 33558100
[TBL] [Abstract][Full Text] [Related]
17. Pancreatic duct organoid swelling is chloride-dependent.
O'Malley Y; Zarei K; Vanegas OGC; Singh P; Apak TI; Coleman M; Thornell IM; Uc A
J Cyst Fibros; 2024 Jan; 23(1):169-171. PubMed ID: 37633792
[TBL] [Abstract][Full Text] [Related]
18. Potentiators (specific therapies for class III and IV mutations) for cystic fibrosis.
Patel S; Sinha IP; Dwan K; Echevarria C; Schechter M; Southern KW
Cochrane Database Syst Rev; 2015 Mar; (3):CD009841. PubMed ID: 25811419
[TBL] [Abstract][Full Text] [Related]
19. A functional CFTR assay using primary cystic fibrosis intestinal organoids.
Dekkers JF; Wiegerinck CL; de Jonge HR; Bronsveld I; Janssens HM; de Winter-de Groot KM; Brandsma AM; de Jong NW; Bijvelds MJ; Scholte BJ; Nieuwenhuis EE; van den Brink S; Clevers H; van der Ent CK; Middendorp S; Beekman JM
Nat Med; 2013 Jul; 19(7):939-45. PubMed ID: 23727931
[TBL] [Abstract][Full Text] [Related]
20. CFTR genotype and clinical outcomes of adult patients carried as cystic fibrosis disease.
Bonadia LC; de Lima Marson FA; Ribeiro JD; Paschoal IA; Pereira MC; Ribeiro AF; Bertuzzo CS
Gene; 2014 May; 540(2):183-90. PubMed ID: 24583165
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
